Related Experiment Video
Updated: Jul 7, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell
Satoshi Hashino1, Lena Morita, Mutsumi Takahata
1Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo 060-8638, Japan. shashino@med.hokudai.ac.jp
Abstract:
Invasive fungal infection is one of the major causes of death in neutropenic patients undergoing allogeneic stem cell transplantation (SCT). Although prophylactic antifungal therapy with fluconazole (FLCZ) has become the standard care for these patients, there remains a need for more effective and cost-beneficial alternative drugs. We conducted a prospective study to evaluate the usefulness of the administration of micafungin (MCFG) as a prophylactic antifungal therapy for patients undergoing allogeneic SCT. The results were compared with previous data for patients who had received FLCZ. A total of 44 patients who underwent allogeneic SCT were enrolled in the study. Data from 29 patients who received allogeneic SCT using prophylactic FLCZ before this study were used as historical control data. Underlying diseases included acute leukemia (n = 16), non-Hodgkin's lymphoma (n = 11), myelodysplastic syndrome (n = 6), and others (n = 11) in the MCFG group and acute leukemia (n = 18), chronic myelogenous leukemia (n = 6), and others (n = 5) in the FLCZ group. The median durations of administration of MCFG and FLCZ were 36 and 34 days, respectively. Prophylactic success, defined as the absence of proven, probable, and possible invasive fungal infection (IFI) until the end of prophylactic therapy was achieved in 36 (87.8%) of the 41 evaluated patients in the MCFG group and in 65.5% of the patients in the FLCZ group (P = 0.038). No patients in the MCFG group showed proven or probable IFI, whereas proven or probable IFI was observed in three patients in the FLCZ group. Four patients in the MCFG group required dose escalation due to febrile neutropenia. Although one patient in the MCFG group required the discontinuation of MCFG due to allergic skin eruption (grade 2), none of the other patients in either group required dose reduction due to adverse effects. Although the study design was not a prospective randomized trial, our results indicate that the administration of MCFG at a daily dose of 100 mg is promising for prophylactic antifungal therapy in patients undergoing allogeneic SCT.
Insights
Micafungin (MCFG) shows promise as a prophylactic antifungal therapy for patients undergoing allogeneic stem cell transplantation (SCT), significantly reducing invasive fungal infections compared to fluconazole (FLCZ). This study suggests MCFG is a potentially more effective and safer option for this high-risk patient population.
Area of Science:
- Hematology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFI) are a leading cause of mortality in neutropenic patients post-allogeneic stem cell transplantation (SCT).
- Current standard prophylactic antifungal therapy with fluconazole (FLCZ) has limitations, necessitating exploration of alternative agents.
- Micafungin (MCFG) is an echinocandin antifungal with potential for IFI prophylaxis in immunocompromised patients.
Purpose of the Study:
- To prospectively evaluate the efficacy and safety of micafungin (MCFG) for prophylactic antifungal therapy in patients undergoing allogeneic SCT.
- To compare the outcomes of MCFG prophylaxis with historical data of FLCZ prophylaxis in a similar patient cohort.
Main Methods:
- A prospective study involving 44 patients undergoing allogeneic SCT receiving prophylactic MCFG (100 mg daily).
- Comparison with a historical control group of 29 patients who received prophylactic FLCZ.
- Evaluation of prophylactic success defined as the absence of proven, probable, or possible IFI until the end of therapy.
Main Results:
- Prophylactic success was achieved in 87.8% of patients receiving MCFG versus 65.5% receiving FLCZ (P = 0.038).
- No patients in the MCFG group developed proven or probable IFI, compared to three in the FLCZ group.
- MCFG was generally well-tolerated, with only one patient discontinuing therapy due to an allergic reaction; dose escalation was required in four patients for febrile neutropenia.
Conclusions:
- Daily administration of micafungin (100 mg) appears to be a promising prophylactic antifungal strategy for patients undergoing allogeneic SCT.
- MCFG demonstrated superior efficacy in preventing invasive fungal infections compared to fluconazole in this study.
- The safety profile of MCFG was favorable, suggesting it as a viable alternative for IFI prophylaxis in this high-risk population.
Related Concept Videos
01:27Cryptococcal Meningitis
01:15Antifungal Agents
01:28Fungal Phylum Microsporidia
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:20Candidiasis